Physician profile
Karen E Rule
NPI 1164492039
$1,933.37
in general payments reported to CMS, 2019-2025
19 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $11.81 · 2021: $156 · 2022: $293 · 2023: $309 · 2024: $536 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $354.41 | 2019-2025 | Cequa |
| Alcon Vision LLC | $215.65 | 2024-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $171.83 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.43 | 2019 | |
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Glaukos Corporation | $128.27 | 2022 | |
| Shire North American Group INC | $124.00 | 2019 | |
| Dompe US, INC. | $124.00 | 2023 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $114.74 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $109.99 | 2024 | Syfovre |
| Maculogix, INC. | $78.44 | 2019 | |
| Bausch & Lomb Americas INC. | $37.14 | 2024 | Miebo, Xiidra |
| Allergan, INC. | $33.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.51 | 2020-2021 | |
| Oyster Point Pharma, INC. | $26.51 | 2022-2023 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.55 | 2023 | Vuity, Lumigan |
| Harrow Eye, LLC | $19.03 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $18.82 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Rule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.